Authors : Ashwini G, Maheshwar N
DOI : 10.18231/j.ijceo.2019.066
Volume : 5
Issue : 3
Year : 2019
Page No : 275-278
Introduction: To assess intraocular pressure variation after intravitreal bevacizumab injection in patients with diabetic macular edema.
Materials and Methods: Our prospective study included 20 eyes of patients who received intravitreal injection of 0.05 ml bevacizumab as treatment option for diabetic macular edema. IOP was recorded before the injection, at 3 days, 1week, 1month and 2 months after the intravitreal injection.
Results: The mean intraocular pressure before injection was 17.28±3.04 mmHg. The mean IOP post bevacizumab at 3 days, 1 week, 1month and 2 months were 19.98± 3.23mmHg, 18.99±3.67 mmHg, 17.31±3.19 and 17.15±3.10 respectively. There was statistically significant elevation in IOP at 3 days post bevacizumab injection, which reinstated to baseline levels at final follow-up.
Conclusion: Our study indicate that intravitreal injection of bevacizumab is associated with short term IOP elevation.
Keywords: Bevacizumab, Clinically significant macular edema, Diabetic macular edema, GAT, IOP.